I am doing an analysis on EU's policies on - and funding for - sexual and reproductive health R&I; I've been looking in Horizon Europe's Strategic Plan and Work Programmes, the EU GHS, GAP III and the GES, and I find nothing. No mention of issues like contraception, menstrual health, eclampsia, post-partum hemorrhage, and barely anything on STIs. There are some commitments on HPV (Mission and Action Plan on Cancer). The word "women" is mentioned *once* in the 101 pages of Horizon Europe Strategic Plan (2021-2024). Once. Am I missing something or are these issues completely overlooked in EU R&D? Ursula von der Leyen Iliana Ivanova
Kasia Lemańska’s Post
More Relevant Posts
-
On International Contraception Day, it is crucial to recall that сontraception protects against not only unwanted pregnancies but also sexually transmitted infections. While women used to bear the burden of responsibility for contraception and the negative consequences and risks of it, today, this responsibility is shared between partners. More new contraceptive methods are being developed for both women and men, creating better opportunities for shared management of reproductive health and family planning. In the post, we will explore the revolutionizing contraception products and services. In the Miranna app, you can discuss with your intimacy coach any aspect of your sexual well-being and intimate relationships. Join us to start a journey to your best self. P.S. In the infographic, we highlighted the following companies: YourChoice Therapeutics, Daye, Nurx from Thirty Madison, Remi Health, Zults™, Hervana Bio Ltd., Dama Health
To view or add a comment, sign in
-
Check out this blog from partners at Population Council, Reproductive Health Supplies Coalition, and Population Services International that highlights how vital end-user feedback is in the development of responsive MPTs that prevent pregnancy, HIV and other STIs: https://lnkd.in/eshRdh9v CAMI Health, Bethany Young Holt, PhD, MPH, Public Health Institute, Male Contraceptive Initiative
Research and development of new multipurpose prevention technologies (MPTs) benefits from feedback earlier in the process, as detailed in this blog from Population Council, Reproductive Health Supplies Coalition, and Population Services International. By bringing end users into the process, and building in more inclusive research practices, developers can design more responsive MPTs. “Approaches to contraceptive development that prioritize the voices of end-users can help meet diverse needs and desires for new contraceptives globally….However, as new products are developed, including novel methods of male contraception, there is an urgent need to do this among men and other gender diverse groups.” Bethany Young Holt, PhD, MPH, The Initiative for MPTs (IMPT), Public Health Institute, Male Contraceptive Initiative
To view or add a comment, sign in
-
FHI 360 is leading a Phase I clinical trial for a biodegradable contraceptive implant—the first for this type of implant in over 20 years. Called Casea S, the long-acting method wouldn't require a visit to a health care provider for removal and has the potential to address some of the barriers people may face when seeking care. “Improving contraceptive access requires diversifying the variety of available methods. We believe that Casea S can offer a new and exciting contraceptive option and fill a gap in the contraceptive method mix,” says Kavita Nanda, MD, MHS, principal investigator of the Casea S study. #Contraception #Contraceptive #FamilyPlanning #FP #SexualAndReproductiveHealthandRights #SRHR https://lnkd.in/gtFFzcFQ
FHI 360 conducting trial for Casea S, a biodegradable contraceptive implant
fhi360.org
To view or add a comment, sign in
-
Review your preventive care coverage for 2025. The IRS issues new guidance for diabetes, contraception and breast cancer services https://ow.ly/fZxP50UaL8q #EmployeeBenefits #HealthInsurance #HealthBenefits #WTWPerspective
To view or add a comment, sign in
-
Article in @dazed about women turning their backs on hormonal contraceptives - combined pill, progestin-only or mini pill and the injection are 30% down now compared to pre pandemic. (Though I wonder what difference allowing pharmacies to prescribe is now making?) When I’m out and about talking about my book Everything You Need to Know About the Pill, which looks into this, it’s clear women are now sharing more about side effects on social media and questioning being gaslighted about them. But there’s also better news - the newer pills like Zoely, Drovelis and Qlaira which contain better body-identical estrogen (but still the same old synthetic progestins) and also the fact that the smaller, lower-dose coils have less risk of depression. But what we really need is a great non-hormonal option and new male contraception, both of which are in the research pipeline - but we’ve still had to wait over 60 years for these improvements 🙄 https://lnkd.in/eJ5d6cR6
To view or add a comment, sign in
-
Review your preventive care coverage for 2025. The IRS issues new guidance for diabetes, contraception and breast cancer services https://ow.ly/6k4y50UcaNn #EmployeeBenefits #HealthInsurance #HealthBenefits #WTWPerspective
To view or add a comment, sign in
-
Tonight **Wednesday November 20th at 8 pm ET** Does use of progestogens increase risk of meningiomas? A webinar with medical and legal experts to address a recent study. What is the risk? What do we document in the chart? Join us for a discussion regarding the facts behind the study results, legal considerations, and guidance for addressing patients’ concerns with clarity and confidence. Register here: https://lnkd.in/eKe8i-5f #womenshealth #ObGyn #contraception
To view or add a comment, sign in
-
According to a 2017-2019 National Survey on Family Growth, the most common contraceptive methods used are: (1) Female sterilization (2) Oral contraceptive pills (3) Long-acting reversible contraceptives (LARCs) (4) The male condom We remain committed to ensuring healthcare professionals have stable pricing and dependable access to the products and services they need to help provide the care of choice for their patients seeking reproductive and sexual healthcare like contraception. See more stats via Centers for Disease Control and Prevention - https://lnkd.in/g-AxPmPQ
To view or add a comment, sign in
-
Can the coil help with endometriosis? Many women with endometriosis have wondered about this. While the coil, also known as an intrauterine device (IUD), is primarily used for contraception, it has been found to offer some relief for women with endometriosis-related pain. The hormone-releasing IUD, such as the Mirena, releases progestin, which may help alleviate the symptoms of endometriosis, including pelvic pain and heavy menstrual bleeding. Additionally, the IUD's presence in the uterus can help inhibit the growth of endometrial tissue outside the uterus, potentially reducing the progression of the condition. However, it's important to note that the effectiveness of the IUD in managing endometriosis symptoms can vary from person to person. It's crucial for women with endometriosis to discuss their options with a healthcare professional such as us, to determine the best course of treatment for their individual needs. You can reach us at: https://lnkd.in/evCanT2j #enometriosisawareness
To view or add a comment, sign in
-
Biodegradable contraceptive implants under development offer the potential for expanded choice for long-acting contraception with the benefit of no removal. This study explored potential user, provider, and other stakeholder perspectives in Kenya and Senegal on 2 biodegradable contraceptive implant prototypes currently in development, revealing potential opportunities and challenges for product introduction. The findings highlight that introduction and marketing efforts will need to consider messaging around product characteristics. https://lnkd.in/gsnsVjXE
To view or add a comment, sign in
Head of Brussels Office | Head of Advocacy Unit, EU at Deutsche Stiftung Weltbevoelkerung (DSW)
2moCame to the same shocking conclusion when mapping EU support to women's health R&D. Good thing that the mission letter to the Commissioner-designate for Preparedness and Crisis Management, and Equality (interesting portfolio ^^) refers to the development of a new Gender Equality Strategy that should inter alia address discrimination in health 🤞